MedCap AB (publ) operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MedCap AB (publ) with three other
pharmaceutical manufacturers in Europe:
Eczacibasi Ilac Sanayi ve T.A.S.
sales of 877.08 million Turkish Liras [US$109.61 million]
of which 85%
New Nordic Healthbrands AB
(452.61 million Swedish Kronor [US$52.95 million]
Science In Sport Plc
based in UNITED KINGDOM
(£50.57 million [US$67.52 million]
of which 51%
MedCap AB (publ) reported sales of SEK 757.10 million (US$88.57 million)
December of 2019.
increase of 6.8%
versus 2018, when the company's sales were SEK 709.00 million.
Despite this increase, sales are still
below the level achieved in 2017, when MedCap AB (publ)
reported sales of SEK 799.94 million.
The sales level in 2019 was fairly close to the level five years ago: in 2014, MedCap AB (publ) had sales
of SEK 826.09 million.
Sales of Medical Technology saw an increase
7.6% in 2019, from
SEK 400.20 million to SEK 430.60 million.